Wedbush Downgrades Insituform Technologies (INSU) to Neutral; Greater-than-Expected Challenges Drive Guidance Lower
Get Alerts INSU Hot Sheet
Price: $11.66 --0%
Rating Summary:
4 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 23 | New: 12
Rating Summary:
4 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 23 | New: 12
Join SI Premium – FREE
Wedbush downgraded Insituform Technologies (NASDAQ: INSU) from Outperform to Neutral with a price target lowered from $20 to $13.
Wedbush analyst says, "Reducing rating on heels of dramatically lower visibility of business - Management’s dramatic reduction in earnings guidance suggests execution, project timing, and forecasting challenges are more complex than we anticipated. Given the company’s persistent challenges, coupled with poor earnings visibility, we are reducing our rating...We are reducing our 2011 EPS estimates to $0.88 from $1.28, $0.02 below the low end of guidance. For 2012, we are lowering our estimate to $1.49 from $1.91."
For more ratings news on Insituform Technologies click here and for the rating history of Insituform Technologies click here.
Shares of Insituform Technologies closed at $13.36 yesterday.
Wedbush analyst says, "Reducing rating on heels of dramatically lower visibility of business - Management’s dramatic reduction in earnings guidance suggests execution, project timing, and forecasting challenges are more complex than we anticipated. Given the company’s persistent challenges, coupled with poor earnings visibility, we are reducing our rating...We are reducing our 2011 EPS estimates to $0.88 from $1.28, $0.02 below the low end of guidance. For 2012, we are lowering our estimate to $1.49 from $1.91."
For more ratings news on Insituform Technologies click here and for the rating history of Insituform Technologies click here.
Shares of Insituform Technologies closed at $13.36 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bicara Therapeutics Inc (BCAX) PT Raised to $39 at BTIG
- National CineMedia (NCMI) Misses Q2 EPS by 7c
- Erasca, Inc. (ERAS) Misses Q2 EPS by 3c
Create E-mail Alert Related Categories
DowngradesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share